Alunbrig efficacy?

Alunbrig (brigatinib) is an ALK inhibitor used for ALK-positive non-small cell lung cancer. Here’s a concise view of its efficacy from key trials:

- First-line ALK-positive NSCLC (ALTA-1L trial)
- Brigatinib vs crizotinib improved progression-free survival (PFS).
- PFS benefit: roughly a 40–45% reduction in risk of progression or death (hazard ratio around 0.55 in reports).
- Median PFS: on the order of a year plus for crizotinib vs markedly longer for brigatinib in early reports (often cited as roughly 24 months with brigatinib vs ~11 months with crizotinib in summaries).
- CNS activity: brigatinib had better control of brain metastases (lower CNS progression, higher intracranial response rates) than crizotinib.
- OS data were not mature at the initial report; subsequent updates have been mixed and not yet definitive in all analyses.

- After progression on crizotinib (second-line or later)
- Brigatinib has meaningful anti-tumor activity in this setting.
- Objective response rates (ORR) typically in the range of about 40–60%.
- Median duration of response around roughly 9–12 months.
- Notable intracranial activity; brain metastases can respond to brigatinib.

- Overall survival (OS)
- In first-line use, OS data were not mature in early reports. Some updates suggest possible OS benefit, but results have not been uniformly definitive across analyses.

- Safety signals to know
- Common side effects: nausea, fatigue, diarrhea, hypertension, headache.
- Early pulmonary/ILD risk: brigatinib has a boxed warning for pulmonary events; to mitigate, a stepped-up dosing approach is used (e.g., initial lower-dose lead-in before increasing to the full dose).
- Drug interactions: metabolism via CYP3A; monitor with strong CYP3A inhibitors/inducers.

If you’d like, I can tailor the summary to a specific setting (first-line vs after crizotinib) and provide the exact trial citations and the latest numbers.